Recombinant human DLL4 protein (Fc Chimera Active)
- Bioactive
- What is this?
Be the first to review this product! Submit a review
|
(7 Publications)
Recombinant human DLL4 protein (Fc Chimera Active) is a Human Fragment protein, in the 1 to 529 aa range, expressed in HEK 293 cells, with >95%, < 0.01 EU/µg endotoxin level, suitable for SDS-PAGE, FuncS.
View Alternative Names
UNQ1895/PRO4341, DLL4, Delta-like protein 4, Drosophila Delta homolog 4, Delta4
- FuncS
Unknown
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
Adipogenesis inhibition of 3T3L-1 cells.
3T3L-1 cells (mouse pre-adipocyte cells) were maintained in DMEM, supplemented with 10% fetal bovine serum and penicillin-streptomycin. For differentiation of 3T3L-1 cells, 3T3L-1 cells were cultured in adipogenic medium which was growth medium supplemented with 1 μM Dexamethasone, 0.5 mM IBMX, 10 μg/ml lnsulin (day 0). Medium was changed every 2 days. Staining with Oil Red O was typically performed on day 7. Cells were washed twice with PBS, fixed with 3.7% formalin, and stained with 0.5% filtered Oil Red O in propylene glycol. For negative controls, mouse TNF-α (20 ng/ml) was added. Recombinant Human DLL4-Fc (ab108557) (5 μg/ml) dissolved in DPBS was added to the differentiation medium. These plates were then used to differentiate 3T3L-1 cells.
- FuncS
Unknown
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
Adipogenesis inhibition of 3T3L-1 cells.
- FuncS
Unknown
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
Adipogenesis inhibition of MSCs.
MSCs (Mesenchymal stem cells) were maintained in DMEM, supplemented with 10% fetal bovine serum, penicilinstreptomycin and glutamine. For differentiation of MSCs, MSCs were cultured in adipogenic medium which was growth medium supplemented with 1 μM Dexamethasone, 0.5mM IBMX, 10 μg/m lnsulin, 100 μM Indomethacin (day 1). Medium was changed every 3 days. Staining with Oil Red O was typically performed on day 30. For negative controls, TNF-α (20 ng/ml) was added. To immobilize Notch ligands on the plastic surface of the culture plates, plates were incubated with a solution of ab108557 (5 μg/ml) or mCD137-Fc (5 μg/ml) in PBS for 2 hours at 37°C. Plates were then used to differentiate MSCs.
- FuncS
Unknown
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
50 μg of cell lysates derived from hDLL4-Fc (ab108557) or non-treated 3T3L-1 cells, which had been either differentiated or undifferentiated, and were subjected to Western blot by using a Mouse adiponectin antibody.
- FuncS
Unknown
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
Interaction of Human Notch1 with Human DLL4.
HEK293 cells transfected with a Human Notch1 or a Human GITR ligand expressing vector were incubated with 25 μg/ml of Human GITR-Fc or ab108557. Cells were stained with anti-Human IgG (Fc specific) FITC conjugate for DLL4-Fc binding.
- FuncS
Unknown
Functional Studies - Recombinant human DLL4 protein (Fc Chimera Active) (AB108557)
Induction of Hes-1 with the treatment of recombinant Human DLL4-Fc (ab108557).
A Mouse preadpipocyte cell line, 3T3L-1, was stimulated with 5 μg/ml of Human DLL4-Fc as in indicated time points and each cell lysate was prepared and subjected to western blot by using anti-Mouse Hes1 or GAPDH.
M : Marker.
Lane 1 : hDLL4-Fc, 0 min.
Lane 2 : hDLL4-Fc, 10 min.
Lane 3 : hDLL4-Fc, 30 min.
Lane 4 : hDLL4-Fc, 1 hr.
Lane 5 : hDLL4-Fc, 2 hr.
Lane 6 : hDLL4-Fc, 4 hr.
Lane 7 : hDLL4-Fc, 8 hr.
Lane 8 : hDLL4-Fc, 24 hr.
Reactivity data
Product details
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
DLL4 engages in precise regulation of angiogenesis and vascular development. It participates in the Notch signaling pathway playing an integral role in controlling endothelial cell proliferation differentiation and migration. DLL4 does not operate in isolation; instead it functions as part of the Notch receptor-ligand complex. This relationship effectively regulates the sprouting of new blood vessels ensuring proper vascular patterning and functional blood supply.
Pathways
DLL4 links directly to the Notch signaling and VEGF (vascular endothelial growth factor) pathways both of which play critical roles in vascular development and homeostasis. Through the Notch pathway DLL4 interacts with Notch1 and Notch4 receptors facilitating communication that inhibits endothelial cell proliferation distinguishing it from other pro-angiogenic factors. Its relationship with the VEGF pathway allows DLL4 to modulate angiogenic processes balancing vessel sprouting by opposing excessive VEGF-induced activities.
Specifications
Form
Lyophilized
Additional notes
Purified using affinity chromatography.
General info
Function
Involved in the Notch signaling pathway as Notch ligand (PubMed : 11134954). Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting (PubMed : 20616313). Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types (By similarity). During spinal cord neurogenesis, inhibits V2a interneuron fate (PubMed : 17728344).
Target data
Additional targets
Publications (7)
Recent publications for all applications. Explore the full list and refine your search
iScience 25:104306 PubMed35602952
2022
Applications
Unspecified application
Species
Unspecified reactive species
Clinical cancer research : an official journal of the American Association for Cancer Research 26:669-678 PubMed31672772
2019
Applications
Unspecified application
Species
Unspecified reactive species
Cellular signalling 54:130-138 PubMed30529759
2018
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 8:6392 PubMed29686270
2018
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 7:43926 PubMed28266574
2017
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 6:22467-79 PubMed26093085
2015
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 289:12016-28 PubMed24599951
2014
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com